Skip to main content

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9?Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

CRISPR Therapeutics

Start Date

May 13, 2021

End Date

September 5, 2026
 

Administered By

Duke Cancer Institute

Awarded By

CRISPR Therapeutics

Start Date

May 13, 2021

End Date

September 5, 2026